<DOC>
	<DOCNO>NCT02863991</DOCNO>
	<brief_summary>ONC201 orally bioavailable first-in-class small molecule demonstrate antitumor activity preclinical model difficult-to-treat solid liquid tumor without impart significant toxicity . This Phase 1/2 open-label study ONC201 administer orally every week combination dexamethasone patient relapsed/refractory multiple myeloma . Funding Source - FDA OOPD</brief_summary>
	<brief_title>Oral ONC201 Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>1 . Patients must refractory , candidate , establish therapy know provide clinical benefit malignancy . 2 . Measurable disease M protein component serum ( least 0.5 g/dL ) and/or urine ( present ) ( &gt; =0.2 g excrete 24 hour collection sample ) . 3 . All previous therapy cancer , include radiotherapy , major surgery investigational therapy discontinue ≥ 14 day ( ≥ 28 day mitomycin C nitrosoureas ) study entry , acute effect prior therapy resolve baseline severity Grade ≤ 1 Common Terminology Criteria Adverse Events ( CTCAE v4.03 ) , except alopecia parameter define eligibility list . 4 . Age ≥ 18 year . 5 . ECOG performance status ≤ 1 . 6 . Adequate organ marrow function define : 1 . Absolute neutrophil count ≥1,000/mm3 without growth factor use ≤ 7 day prior treatment ( cycle 1 day 1 , C1D1 ) 2 . Platelets ≥75,000/mm3 without platelet transfusion ≤ 3 day prior C1D1 3 . Hemoglobin &gt; 8.0 mg/dL without red blood cell transfusion ≤ 3 day prior C1D1 4 . Total serum bilirubin &lt; 1.5 X upper limit normal ( ULN ) 5 . AST ( SGOT ) /ALT ( SGPT ) ≤2 X ULN ; ≤ 5 X ULN liver involvement secondary tumor 6 . Serum creatinine ≤ 1.5 X ULN ( OR creatinine clearance ≥ 60 mL/min/1.73 m2 ) 7 . Serum urine pregnancy test ( female childbearing potential ) negative ≤7 day start treatment 7 . Ability understand willingness sign write informed consent document comply study schedule visit , treatment plan , laboratory test procedure . 8 . Female patient must surgically sterile postmenopausal , must agree use effective contraception period trial least 90 day completion treatment . Male patient must surgically sterile must agree use effective contraception period trial least 90 day completion treatment . The decision effective contraception base judgment principal investigator designate associate . 1 . Active inflammatory gastrointestinal disease , chronic diarrhea ( unless relate underlying malignancy prior related treatment ) history abdominal fistula , gastrointestinal perforation , peptic ulcer disease , intraabdominal abscess within 6 month prior study enrollment . Gastroesophageal reflux disease treatment proton pump inhibitor allow . 2 . Pregnancy breast feed . 3 . Current active treatment another clinical study . 4 . Active bacterial , fungal viral infection include hepatitis B ( HBV ) , hepatitis C ( HCV ) 5 . Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness well control . 6 . Active prior plasma cell leukemia ( define either 20 % peripheral WBC comprise plasma/CD138+ cell absolute count 2 x 10^9/L ) . 7 . Solitary bone solitary extramedullary plasmacytoma evidence plasma cell dyscrasia . 8 . Subjects serum calcium ( correct albumin ) ≥ 12 mg/dL 9 . Any following previous 6 month : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack symptomatic pulmonary embolism . 10 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>